Identification of a novel HLA-B*55 variant (B*5513) from a Korean family

Tissue Antigens

Volumn 64, Issue 1, 2004, Pages 96-98

  Park, H S ^a   Choi, J H ^a   Lee, K W ^b,c  

^a Ajou University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Hallym University Sacred Heart Hospital   (South Korea)

Author keywords

B*5513; HLA B*55; Korean; Novel allele; PCR SBT

Indexed keywords

HLA ANTIGEN; HLA B55 ANTIGEN; LEUCINE; PHENYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ANTIGEN DETECTION; ARTICLE; CODON; DNA SEQUENCE; GENE FREQUENCY; HUMAN; KOREA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; DNA; EXONS; HLA-B ANTIGENS; HUMANS; KOREA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 3042742393     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-2815.2004.00249.x     Document Type: Article

References (9)

1. Lee KW, Yang SY. HLA-B22 diversity including a novel B54 variant (B*5507) in the Korean population. Hum Immunol 1999: 60: 731-7.
2. Hurley CK. Sequence-based typing for HLA-B: class-I sequencing amplification of exons 2 and 3 based upon Cereb. In: Tilanus MGJ, Hansen JA, Hurley CK, eds. IHWG Technical Manual. Seattle, International Histocompatibility Working Group, 2000, TM8A1-5.
3. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SG. IMGT/HLA database - a sequence database for the human major histocompatibility complex. Tissue Antigens 2000: 55: 280-7.
4. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class-I histocompatibility antigen, HLA-A2. Nature 1987: 329: 506-12.
5. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen-binding site and T-cell recognition regions of class-I histocompatibility antigens. Nature 1987: 329: 512-8.
6. Kubo H, Ikeda-Moore Y, Kikuchi A et al. Residue 116 determines the C-terminal anchor residue of HLA-B*3501 and -B*5101-binding peptides but does not explain the general affinity difference. Immunogenetics 1998: 47: 256-63.
7. Dong T, Boyd D, Rosenberg W et al. An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. Eur J Immunol 1996: 26: 335-9.
8. Khanna R, Silins SL, Weng Z, Gatchell D, Burrows SR, Cooper L. Cytotoxic T-cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction. Eur J Immunol 1999: 29: 1587-97.
9. Ferrara GB, Bacigalupo A, Lamparelli T et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class-I heavy chain. Blood 2001: 98: 3150-5.